

Clinical criteria updates for specialty pharmacy

Published: Oct 1, 2021 - **Products & Programs** / Pharmacy

The following clinical criteria documents were endorsed at the August 20, 2021 Clinical Criteria meeting. Visit our [website](#) to access the clinical criteria information.

Revised clinical criteria effective September 1, 2021

The following criteria were revised to expand medical necessity indications or criteria.

- ING-CC-0020: Tysabri (natalizumab)
- ING-CC-0062: Tumor Necrosis Factor Antagonists
- ING-CC-0124: Keytruda (pembrolizumab)

Revised clinical criteria effective September 1, 2021

The following criteria were reviewed and may have word changes or clarifications, but had no significant changes to the policy position or criteria.

- ING-CC-0007: Synagis (palivizumab)

Revised clinical criteria effective September 20, 2021

The following criteria were reviewed and may have word changes or clarifications, but had no significant changes to the policy position or criteria.

- ING-CC-0004: H.P. Acthar Gel (repository corticotropin injection)
- ING-CC-0011: Ocrevus (ocrelizumab)
- ING-CC-0014: Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis
- ING-CC-0030: Implantable and ER Buprenorphine Containing Agents
- ING-CC-0035: Duopa (carbidopa and levodopa enteral suspension)
- ING-CC-0036: Naltrexone Implantable Pellets
- ING-CC-0044: Exondys 51 (eteplirsen)
- ING-CC-0058: Octreotide Agents

- ING-CC-0082: Onpattro (patisiran)
- ING-CC-0100: Istodax (romidepsin)
- ING-CC-0139: Evenity (romosozumab-aqqg)
- ING-CC-0144: Lumoxiti (moxetumomab pasudotox-tdfk)
- ING-CC-0152: Vyondys 53 (golodirsen)
- ING-CC-0167: Rituximab Agents for Oncologic Indications Step Therapy
- ING-CC-0172: Viltepso (viltolarsen)
- ING-CC-0174: Kesimpta (ofatumumab)
- ING-CC-0176: Beleodaq (belinostat)
- ING-CC-0179: Blenrep (belantamab mafodotin-blmf)
- ING-CC-0180: Monjuvi (tafasitamab-cxix)
- ING-CC-0181: Veklury (remdesivir)
- ING-CC-0189: Amondys 45 (casimersen)
- ING-CC-0191: Pepaxto (melphalan flufenamide; melflufen)

Revised clinical criteria effective September 20, 2021

The following criteria were revised to expand medical necessity indications or criteria.

- ING-CC-0001: Erythropoiesis Stimulating Agents
- ING-CC-0010: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors
- ING-CC-0038: Human Parathyroid Hormone Agents
- ING-CC-0075: Rituximab Agents for Non-Oncologic Indications
- ING-CC-0104: Levoleucovorin Agents
- ING-CC-0169: Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
- ING-CC-0193: Evkeeza (evinacumab)

Revised clinical criteria effective October 1, 2021

The following criteria were updated with new procedure and/or diagnosis codes.

- ING-CC-0100: Istodax (romidepsin)
- ING-CC-0126: Blincyto (blinatumomab)
- ING-CC-0150: Kymriah (tisagenlecleucel)
- ING-CC-0151: Yescarta (axicabtagene ciloleucel)
- ING-CC-0168: Tecartus (brexucabtagene autoleucel)
- ING-CC-0171: Zepzelca (lurbinectedin)

- ING-CC-0173: Enspryng (satralizumab-mwge)
- ING-CC-0182: Iron Agents
- ING-CC-0187: Breyanzi (lisocabtagene maraleucel)
- ING-CC-0189: Amondys 45 (casimersen)
- ING-CC-0191: Pepaxto (melphalan flufenamide; melflufen)
- ING-CC-0192: Cosela (trilaciclib)
- ING-CC-0193: Evkeeza (evinacumab)
- ING-CC-0194: Cabenuva (cabotegravir extended-release; rilpivirine extended-release)
Injection
- ING-CC-0195: Abecma (idecabtagene vicleucel)
- ING-CC-0196: Zynlonta (loncastuximab tesirine-lpyl)
- ING-CC-0197: Jemperli (dostarlimab)
- ING-CC-0201: Rybrevant (amivantamab-ymjw)

New clinical criteria effective January 1, 2022

The following clinical criteria are new.

- ING-CC-0202: Saphnelo (anifrolumab-fnia)
- ING-CC-0203: Breyanzi Ryplazim (plasminogen, human-tvmh)

Revised clinical criteria effective January 1, 2022

The following criteria listed below might result in services that were previously covered, but now being considered not medically necessary.

- ING-CC-0001: Erythropoiesis Stimulating Agents
- ING-CC-0009: Lemtrada (alemtuzumab) for the Treatment of Multiple Sclerosis
- ING-CC-0010: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors
- ING-CC-0027: Denosumab Agents
- ING-CC-0029: Dupixent (dupilumab)
- ING-CC-0034: Hereditary Angioedema Agents
- ING-CC-0038: Human Parathyroid Hormone Agents
- ING-CC-0081: Crysvida (burosumab-twza)
- ING-CC-0096: Asparagine Specific Enzymes
- ING-CC-0104: Levoleucovorin Agents
- ING-CC-0156: Reblozyl (luspatercept)
- ING-CC-0182: Agents for Iron Deficiency Anemia

1339-1021-PN-NE

URL: <https://providernews.anthem.com/maine/article/clinical-criteria-updates-for-specialty-pharmacy-65>

Featured In:

October 2021 Anthem Connecticut Provider News, October 2021 Anthem New Hampshire Provider News, October 2021 Anthem Maine Provider News

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by Compcare or WCIC; Compcare Health Services Insurance Corporation (Compcare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.
